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Background: Chlamydia trachomatis infections in pregnancy can cause maternal disease, adverse pregnancy
outcomes and neonatal disease, which is why chlamydia screening during pregnancy has been advocated. The
effectiveness of a screening program depends on the knowledge of health care professionals, women and
partners and the acceptability for screening of the target population. We assessed the knowledge of chlamydia
infection among pregnant women and their partners in the Netherlands, their attitudes towards testing, and
their experiences of being offered a chlamydia test. In addition, we evaluated the association between participants’
background characteristics and knowledge of chlamydia.
Methods: Pregnant women aged ≤ 30 years and their partners (regardless of their age) attending one of the
participating primary midwifery care practices in the Netherlands were invited to participate. All participants
completed a questionnaire, pregnant women provided a vaginal swab and partners provided a urine sample to
test for C. trachomatis.
Results: In total, 383 pregnant women and 282 partners participated in the study of whom 1.9% women and 2.6%
partners tested chlamydia positive. Participants had high levels of awareness (92.8%) of chlamydial infection. They
were knowledgeable about the risk of chlamydia infection; median knowledge score was 9.0 out of 12.0. Lower
knowledge scores were found among partners (p-value <0.001), younger aged (p-value 0.02), non-western origin
(p-value <0.001), low educational level (p-value <0.001), and no history of sexually transmitted infections (p-value
<0.001). In total, 78% of respondents indicated that when pregnant women are tested for chlamydia, their partners
should also be tested; 54% believed that all women should routinely be tested. Pregnant women more often
indicated than partners that testing partners for chlamydial infection was not necessary (p-value <0.001). The majority
of pregnant women (56.2%) and partners (59.2%) felt satisfied by being offered the test during antenatal care.
Conclusion: Pregnant women and their partners were knowledgeable about chlamydial infection, found testing, both
pregnant women and their partners, for chlamydia acceptable and not stigmatizing.
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Chlamydia trachomatis infection in pregnancy can
cause maternal disease, adverse pregnancy outcomes,
and neonatal disease [1-5]. High chlamydia prevalence
rates have been described among pregnant women
varying from 3.2% to 5.9%, with even higher rates
among pregnant teenagers (14%) [1,6-9]. In general,
approximately 80% of infected women and 50% of
infected men are asymptomatic or minimally symp-
tomatic. Hence, screening is the only means to effect-
ively identify infections [2].
In the Netherlands pregnant women are routinely
tested for HIV, syphilis and hepatitis B, but not for
chlamydia [2,10]. International guidelines recommend
universal chlamydia screening during antenatal care
or screening of pregnant women less than 25 years of
age [11-15]. Studies suggest using either of these
approaches for routine chlamydia screening is cost
effective [6,16]. The Dutch Health Council has no
recommendation specific for pregnant women, but
recommends in general that health care professionals
should actively screen for chlamydial infections in
people who are at higher risk [17]; the latter being
young age, Surinamese or Antillean ethnicity, attend-
ing clinics for STIs, having multiple sexual partners,
and other risk factors in combination with sexual
behaviour or symptoms, partners of chlamydia posi-
tive persons, and mothers of chlamydia positive new-
borns [17]. However, in a previous study we showed
that the decision for Dutch midwives to offer chla-
mydia testing to pregnant women is based on symp-
toms rather than on risk factors [18]. Hence, many
chlamydial infections will remain undetected.
A key factor for the effectiveness of an antenatal
chlamydia screening program is that women and their
partners have knowledge about the infection and that
they accept screening [19]. Only few studied the know-
ledge of chlamydia, attitudes towards chlamydia infection
screening and experiences of being offered a chlamydia
test among pregnant and non-pregnant women, and
their partners [20,21].
The aim of this study was to assess the knowledge of
chlamydia infection among pregnant women and their
partners in the Netherlands and to determine associa-
tions between pregnant women and their partner’s
demographic characteristics and their knowledge on
chlamydia infections. In addition, we assessed their
attitudes towards antenatal chlamydia testing and ex-
periences of being offered a test in antenatal care.
Methods
This study is part of a national cross-sectional study
about the prevalence and risk factors for chlamydia
infection in pregnant women and their partners. Primarycare midwifery practices were invited using a sampling
method based on the location of the practices in the
Netherlands. In total, twenty-two primary midwifery
care practices participated. Pregnant women were eli-
gible for participation if they consulted a midwife in
one of the participating practices between May 2012
and December 2013, were pregnant at the time of
enrolment, had reached the legal age of consent of
18 years, were younger than 31 years of age, and were
able to understand Dutch. Partners of women were
eligible to participate if they were present at the time
their pregnant partner was included, and were able to
understand Dutch. Because chlamydia is more preva-
lent among younger people, we decided to include only
pregnant women younger than 31 years. There was no
age limit for the partners.
The Medical Ethics Committee of the VU University
Medical Center Amsterdam, the Netherlands, approved
the study.
Data collection
The midwife or practice assistant informed pregnant
women and their partners about the study and invited
them to participate. Eligible pregnant women and part-
ners signed an informed consent form. They were asked
to fill in a questionnaire, which contained 37 questions.
In addition they were asked to provide a self-collected
sample (e.g. a vaginal swab for women and urine speci-
men for partners), which was sent to the laboratory for
C. trachomatis testing.
The questionnaire was developed to obtain data on
demographic characteristics, knowledge of the infection,
and attitudes towards testing for chlamydia in antenatal
care. Questions were based on previous studies and the
literature [8,19,22-24]. Questionnaires were provided
with a prepaid return envelope. The informed consent
forms and questionnaires were provided with an unique
anonymized identification number. We conducted a
small pilot study and confirmed the acceptance of this
relatively personal questionnaire among women and
their partners. Demographic characteristics and risk
factors were age at the time of enrolment, highest
achieved level of education, ethnic origin, urbanisation
level, marital status (no partner/having a partner, but
living alone/married or living with a partner), gravidity
(primigravidae versus multigravidae), planned pregnancy
(yes/no) and history of sexually transmitted infections
(STI) (yes/no/never been tested). For the analyses we
categorized some of the demographic characteristics of
the participants. Age was defined as the age at enrol-
ment and categorized into three groups for women:
≤20 years, 21–25 years, 26–30 years. For partners we
used the same age groups as well as an additional group
of ≥31 years. Highest achieved level of education was
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(medium- level secondary education or below), medium
level of education (higher-level secondary education
or vocational education) and high level of education
(diploma level or university education). Ethnic origin
was defined according to the definition used by Statistics
Netherlands, and categorized into Dutch, other western
origin, and non-western origin [25]. Statistics Netherlands
defines someone to be of non-Dutch origin if at least
one of the parents was not born in the Netherlands. In
case the parents were born in two different foreign
countries, the mother’s country of birth prevailed [25].
Urbanisation level was based on the postal code of the
address of the pregnant woman or her partner, stratified
according to “area address density” (AAD), and dichoto-
mized into <2499 addresses/km2 and >2500 addresses/
km2 [26]. The number of pregnancies women experi-
enced was dichotomized into first and multiple preg-
nancies. In addition, pregnant women and partners
were asked whether they had heard about chlamydia
before they participated in the study giving three answer
options: “I had heard of chlamydia and knew it was an
STI”, “I had heard of chlamydia, but did not know it
was an STI”; or “I had never heard of chlamydia before”.
Regarding knowledge of chlamydia, twelve questions
covered pregnant women’ and partners’ knowledge
about the infection. We asked them to indicate which
general statements and transmission routes of the infec-
tion were “true” “false” or they “did not know”. We
presented pregnant women and partners with a list of
six general statements of which one was false, and with
a list of six transmission routes of the infection, of
which three were true and three were false. Knowledge
scores were calculated from the knowledge questions
and each correct answer was given a value of +1, and an
incorrect answer or the ‘don’t know’ option a value of 0.
Therefore the overall knowledge sum score could vary
between 0 and 12. Regarding the attitudes towards test-
ing, we asked pregnant women and partners whether
they agreed with one of five statements about their
attitudes towards testing for chlamydia in pregnant
women: 1) all women should be tested; 2) only women
at increased risk should be tested; 3) only women who
want to be tested should be tested; 4) testing during
pregnancy is not necessary; and 5) I have no opinion
about whether or not pregnant women should be tested.
In addition, we asked pregnant women and partners
whether or not they thought partners of pregnant
women should also be tested for chlamydia during ante-
natal care if the pregnant woman was tested. Finally, we
asked pregnant women and partners about their experi-
ences for being offered a chlamydia test during ante-
natal care by their midwife. Pregnant women and their
partners were asked if they felt satisfied, surprised,stigmatized, ashamed, and whether the test offer had
an emotional impact on them. These answers were re-
corded on a five point Likert scale, graded from 1:
“strongly agree” to 5: “strongly disagree”. The state-
ments were dichotomized into two categories: (strongly)
agreeing (Likert scale 1–2) with the statement versus
neutral or (strongly) disagreeing (Likert scale 3–5) with
the statement.
Chlamydia trachomatis detection
To detect C. trachomatis infection, DNA was isolated
from the vaginal swab or urine specimen by the High
Pure PCR Template Preparation Kit (Roche), and proc-
essed using the new CE-IVD certified PRESTO-PLUS test
(Goffin Molecular Diagnostics, Houten, the Netherlands).
Pregnant women and their partners received the test
result by mail. Those who tested positive for chlamydia
were advised to contact their general practitioner for
treatment. Midwives received the test results of the
pregnant women, but not of the partners. In the current
antenatal care system the partner is not considered as a
midwife’s client. Therefore, midwives did not receive
the partners’ test results.
Data from the informed consent forms and the ques-
tionnaires were linked with chlamydia test results using
anonymized identification numbers.
Analysis
We calculated frequency distributions for questionnaire
items on the separate knowledge questions and the know-
ledge score, attitudes towards chlamydia testing in antenatal
care and experiences for being offered a chlamydia test.
We used the Mann–Whitney U test and Kruskal-
Wallis test for differences in knowledge scores between
subgroups of pregnant women and their partners based
on their characteristics. We used these non-parametric
tests because the knowledge score was not normally
distributed. In addition we used X2-test statistics to
test for differences in knowledge questions between
subgroups of pregnant women and partners, and for
differences between pregnant women and partners in
the experiences of being offered a test. For all analyses
we used SPSS 20.0 (SPSS inc., Chicago, IL).
Results
In total 485 pregnant women from 22 primary midwifery
care practices participated in this study. Of them, 102
pregnant women were excluded from analysis: five did
not have a unique participation code, and 97 did not
return the questionnaire. After exclusion, 383 pregnant
women remained in the study, of whom 286 partners
participated. Four partners were excluded from the study
because they did not return the questionnaire, resulting
in 282 partners included for analyses.
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The median age of the pregnant women was 27 years,
range 18 to 30 years. The median age of the 282 partners
was 30 years, range 18 to 49 years. Vaginal swabs and
urine samples were available from 627 participantsTable 1 Characteristics and median knowledge scores of preg
Subgroups Numbera (%)
Chlamydia trachomatis (n = 627)
Positive negative 14 (2.2)
613 (97.8)
Participants (n = 665)
Pregnant woman partner 383 (57.6)
282 (42.4)
Age group (n = 665)
≤ 20 years 30 (4.5)
21-25 years 147 (22.1)
26-30 years 383 (57.6)
≥ 31 years (partners only) 105 (15.8)
Ethnic origin (n = 659)
Dutch 492 (74.7)
Other western origins 55 (8.3)
Non-western origins 112 (17.0)
Urbanisation (n = 655)
<2499 addresses/km2 529 (80.8)
>2500 addresses/km2 126 (19.2)
Educational level (n = 662)
Low 119 (18.0)
Intermediate 255 (38.5)
High 288 (43.5)
Marital status (n = 381)
Single 10 (2.6)
Partner, but not living together 35 (9.2)
Married or living together 336 (88.2)
Pregnancy planned (n = 383)
No 100 (26.1)
Yes 283 (73.9)
First pregnancy (n = 376)
Yes 217 (57.7)
No 159 (42.3)
History of STI (n = 654)
No 225 (34.4)
Yes 87 (13.3)
Never been tested 342 (52.3)
*Minimum possible score = 0; Maximum possible score = 12.
aDenominator varies due to missing variables (between 0 and 11 missing per item)
bMann–Whitney U test and Kruskal-Wallis test.(94.3%), of which 14 (2.2%) tested positive for chla-
mydia; seven women (1.9%) and seven partners (2.6%).
Two women tested negative while their partner tested
positive. More detailed information about background
characteristics of the participants is shown in Table 1.nant women and partners
Median knowledge
score*
P-valueb Differences in
knowledge scores per
subgroup
.15
8.0
9.0
<0.001
9.0
9.0
.02
8.5
9.0
9.0
9.0
<0.001
9.0
9.0
8.0
.83
9.0
9.0
<0.001
8.0
9.0
9.0
.62
9.5
9.0
9.5
.21
9.0
10.0
.09
10.0
9.0
<0.001
9.0
10.0
9.0
or data is only available for pregnant women.
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In total, 616 (92.8%) pregnant women and their partners
had heard about chlamydia before they participated in
this study and knew that the infection was an STI; 5
(0.8%) of them had heard of chlamydia but did not know
the infection was an STI, and 43 (6.5%) pregnant women
and partners had never heard of chlamydia before they
participated in this study.
Of pregnant women and partners, 81 (12.3%) an-
swered all twelve knowledge questions correctly. The
overall median knowledge score was 9 out of a max-
imum possible score of 12 (range: 0 to 12); and 17
(2.6%) of them scored 0. Table 1 shows the median
knowledge scores per demographic subgroup. Signifi-
cantly higher knowledge scores were found among the
following subgroups: pregnant women, age ≥ 21 years,
Dutch and other western origins, high educational
level and a history of STIs. The correct answers on the
knowledge questions are shown in Table 2. The median
knowledge scores for pregnant women was 9 out of a
possible score of 12 (25th percentile 8, 75th percentile
11); for partners the median knowledge score was 9
out of a possible 12 (25th percentile 7, 75th percentile
10). In general, pregnant women had more knowledge
on both the true and false statements than partners.
Significant differences between pregnant women and
partners in correct answers were found for the state-
ment that chlamydia can be cured by medicines (89.2%
of pregnant women versus 78.6% of partners); that youTable 2 Knowledge concerning Chlamydia trachomatis infecti
Knowledge statements Pregnant women
General questions about Chlamydia trachomatis
True answers
Can you infect people without knowing it? 336 (88.2)
Can chlamydia be cured with medicines? 340 (89.2)
Can you have chlamydia more than once? 256 (67.2)
Can chlamydia cause infertility? 280 (73.5)
Is condom use protective against chlamydia? 300 (78.7)
False answers
Will you always have symptoms when infected? 325 (85.3)
Chlamydia trachomatis can be transmitted by:
True answers
Genital sexual contact with an infected person 349 (91.8)
Anal sexual contact with an infected person 246 (64.7)
Oral sexual contact with an infected person 212 (55.8)
False answers
Kissing an infected person on the mouth 290 (76.3)
A toilet seat 241 (63.4)
Sharing bath towels with an infected person 218 (57.4)
aChi square test.can have a chlamydia infection more than once (67.2%
of pregnant women versus 58.0% of partners); and that
chlamydia can cause infertility (73.5% of pregnant
women versus 64.4% of partners). In addition, pregnant
women indicated significantly more often correctly
“no” to the statement that you always have symptoms
when you are infected (85.3% of pregnant women ver-
sus 71.5% of partners). Pregnant women and partners
were aware that chlamydia infections can be transmit-
ted by genital sexual contact with an infected person.
Pregnant women significantly more often correctly
indicated that you cannot get infected with chlamydia
through toilet seats (63.4) than partners (54.8%). In
addition, women indicated significantly more often
correctly that one cannot get infected with chlamydia
through bath towels (57.4%) than partners (48.0%).
Attitudes towards testing
According to 347 (54.2%) participating pregnant women
and partners, all women should routinely be tested for
chlamydia in antenatal care; 85 (13.3%) reported that
only women at increased risk should be tested; 160
(25.0%) reported that pregnant women should only be
tested if they want to be tested, one persons reported
that testing pregnant women for chlamydia was not
necessary, and 47 (7.3%) reported that they had no opin-
ion about whether or not pregnant women should be
tested for chlamydia in antenatal care. Table 3 shows the
differences in attitudes between pregnant women andon
(n = 383) N (%) Partners (n = 282) N (%) P-valuea
236 (84.0) .15
221 (78.6) <0.001
163 (58.0) .02
181 (64.4) .02
216 (76.9) .63
201 (71.5) <0.001
250 (89.0) .26
169 (60.4) .29
146 (52.1) .40
196 (70.0) .08
154 (54.8) .03
135 (48.0) .02
Table 3 Attitudes towards Chlamydia trachomatis testing during antenatal care
Attitudes towards chlamydial testing Pregnant women (n = 368) N (%) Partners (n = 272) N (%) P-valuea
All pregnant women should be tested 206 (56.0) 141 (51.8) .34
Only pregnant women at increased risk 61 (16.6) 24 (8.8) .01
Only pregnant woman who want to be tested 83 (22.6) 77 (28.3) .12
Testing pregnant women is not necessary 0 (0.0) 1 (0.4) .88
No opinion 18 (4.9) 29 (10.7) .01
aChi-square test.
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Compared to the pregnant women, partners were less
likely to report that only pregnant women at increased
risk should be tested for chlamydia (8.8% partners versus
16.6% pregnant women) and partners were more likely
to have no opinion whether or not pregnant women
should be tested for chlamydia during pregnancy (10.7%
partners versus 4.9% pregnant women). In addition, 512
(78.3%) of the participants indicated that the partners
should also be tested for chlamydia during pregnancy if
the pregnant women was tested; 48 (7.3%) indicated
it was not necessary to test also the partner, and 94
(14.4%) did not have an opinion about whether partners
of pregnant women should be tested. Compared to the
partners, pregnant women indicated more often that
testing partners for chlamydia during pregnancy was not
necessary (10.8% of pregnant women versus 2.6% of
partners, p-value <0.001). Partners indicated more often
than pregnant women that they did not have an opinion
about the statement that it is necessary to test partners
of pregnant women for chlamydia during antenatal care
(10.3% of pregnant women versus 20.1% of partners,
p-value 0.001).
Experiences of being offered a test
The majority of pregnant women (59.2%) and partners
(56.2%) felt satisfied with the test offer for chlamydia,
and for most pregnant women (70.5%) and partners
(69.7%) it had no emotional impact (Table 4). In total,
3.7% of the pregnant women and 1.8% of partners felt
stigmatized by having a chlamydia test offered, and 2.7%
of the pregnant women and 1.1% of the partners felt
ashamed by having a test offered.Table 4 Experiences of being offered a Chlamydia trachomati
Experiences Pregnant women wh
I felt satisfied with the test offer 221 (59.2)
I felt surprised by the test offer 57 (15.2)
I felt stigmatised by the test offer 7 (1.8)
I felt ashamed by the test offer 10 (2.7)
The test offer had no emotional impact on me 265 (70.5)
aPercentage of pregnant women and partners who strongly agree or agree with thDiscussion
This study shows that pregnant women and their part-
ners think that testing women for chlamydia during
antenatal care is acceptable and not stigmatizing.
To our knowledge there are not many studies in in-
dustrialized country that tested both pregnant women
and partners for chlamydia infection during antenatal
care, as well as that we assessed their attitudes towards
testing and experiences of being offered a test. We found
positive attitudes towards screening. However, it is pos-
sible that partners of pregnant women who did not par-
ticipate in this study were less positive about being
tested for chlamydia infection during antenatal care.
Some bias may have occurred in this study. We cannot
comment on the characteristics or reasons for not
participating since the number and reasons for refusal
for both pregnant women and their partners were not
recorded. Furthermore, midwives may not have asked all
eligible pregnant women to participate. Possible explana-
tions may be time constraints or because midwives felt
uncomfortable asking pregnant women to participate in
a chlamydia study. In our previous study we have shown
that midwives are often not comfortable asking pregnant
women about their sexual history. Likewise, they may
feel uncomfortable inviting women and partners to
participate in a chlamydia prevalence study [18]. In
addition, 20% of pregnant women did not return the
questionnaire. It is possible that the women and partners
did not have the commitment to participate, but also
that they did not know the answers to the questions and
therefore not returned the questionnaire. Furthermore,
pregnant women and partners completed the question-
naire at home and may have searched the Internet fors test during antenatal care
o agreea (n = 376) N (%) Partners who agreea (n = 274) N (%)
154 (56.2)
48 (17.5)
10 (3.7)
3 (1.1)
191 (69.7)
e statement.
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facts may have led to an overestimation of the know-
ledge scores and an overoptimistic view on screening
for chlamydia in pregnancy and explain the differences
with other studies among pregnant women and non-
pregnant young women in which lower awareness levels
and knowledge scores for chlamydia infection were
found [20,27]. In addition, our respondents were higher
educated than the general Dutch population. This may
also explain why we found lower prevalence rates of
chlamydia in pregnant women compared with previous
studies.
Unfortunately, we did not investigate the attitudes and
experiences of pregnant women and partners after they
received their chlamydia test result. A positive test result
may influence their future attitudes or experiences [28].
However, studies from Australia showed that chlamydia
infected women, both pregnant and non-pregnant, did
not differ from uninfected women concerning their
attitudes towards testing, and most of them felt re-
lieved and grateful that chlamydia was diagnosed and
treated [20,28]. Testing might be acceptable for preg-
nant women as they could undertake whatever care is
necessary to ensure the health of their baby [20].
The majority of the pregnant women and their part-
ners included in this study were aware about chlamydia
being an STI, unlike the study among pregnant women
in Australia [20]. Again, these results may be an over-
estimation of the actual level of awareness among preg-
nant women and their partners, as the correct answer
was given as one of the answer options. Our results
show differences in knowledge scores between certain
subgroups of participants. Lower knowledge scores were
found among partners, pregnant women and partners
aged 21 years and younger, pregnant women and part-
ners of non-western origin and pregnant women and
partners with a low educational level. These findings are
indirectly comparable with the differential uptake of
chlamydia screening programs in the general population,
as these subgroups often have lower participation rates
[29]. This is important, as these subgroups are also at
higher risk for chlamydia infection [1,8,20].
Our study found that pregnant women and their part-
ners had positive attitudes towards antenatal chlamydia
testing. Although one quarter of the pregnant women
and partners indicated that pregnant women should only
be tested if they want to be tested, the majority indicated
that all pregnant women should be tested for chlamydia.
This indicates high acceptance of testing for chlamydia
during antenatal care. Furthermore, the majority of
participants indicated that the partner of a pregnant
woman should also be tested for chlamydia infection
during antenatal care. These results are comparable with a
study from Sweden in which most of the interviewed menshowed positive attitudes towards testing for HIV and
chlamydia during antenatal care and that this would
make them feel more involved in the pregnancy [30].
This may also explain that partners indicated more
often than pregnant women that testing the partners for
chlamydia during pregnancy was necessary. Partners are
often seen as a psychosocial support for the pregnant
woman, but the biological health risks of transmitting
an STI to the women and their unborn offspring are
usually neglected [30]. Testing partners for chlamydia
may be important, as a Dutch study among asymptom-
atic couples showed that at one time-point only half of
the partners were infected [31]. Hence, it may be pos-
sible that a woman tests negative for chlamydia during
the first trimester of pregnancy while her partner has a
chlamydia infection, which occurred twice in our study.
In that case the pregnant women might get infected by
her partner later during pregnancy. Midwives in the
Netherlands provide only care to pregnant women and
not to their partners. However, women and partners
showed positive attitudes towards partner testing during
pregnancy, which may offer an opportunity to add this
screening to the midwifery scope of practice or to
arrange for testing by a general practitioner or an STI
clinic.
The majority of pregnant women and partners felt
satisfied when they were offered a chlamydia test. Only
a small proportion felt stigmatized or ashamed when
the midwife offered them a test. For midwives it is
necessary to minimize embarrassment by offering cli-
ents appropriate information on chlamydia infection.
In the Netherlands, target screening for chlamydia is
recommended by the Dutch Health Council [17]. How-
ever, target screening has the potential to stigmatize
people, and midwives may not feel comfortable in
asking their clients questions about sexual behaviours
[18]. In addition, Dutch midwives usually base their
decision to offer pregnant women a chlamydia test on
symptoms of the disease [18]. Hence, many cases of
chlamydia remain undetected and untreated, as chla-
mydial infection causes symptoms in only 20% of
women [2]. Routine screening of all pregnant women
will prevent stigmatization. A study that estimated the
cost-effectiveness of chlamydia screening among Dutch
women revealed that screening women for chlamydia dur-
ing pregnancy is cost-effective in the Netherlands [16].
Moreover, pregnant women are often highly motivated
to accept chlamydia testing during antenatal care, as
they are willing to undertake whatever care is necessary
to ensure the health of their offspring [20].
Conclusion
This study showed that pregnant women and their part-
ners were knowledgeable about chlamydia infection and
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These results provide a good basis for introducing a
chlamydia screening programme during pregnancy in
the Netherlands. Since chlamydia can be easily treated,
such program would lower transmission of chlamydia,
maternal disease, adverse pregnancy outcomes and
neonatal disease.
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